CRESCENT BIOPHARMA, INC. — Form 10-Q
Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Joshua Brumm (CEO) and Richard Scalzo (CFO) issued standard Sarbanes-Oxley Section 302 and 906 certifications on July 30, 2026 for the quarterly report ended June 30, 2026. Both officers certified that the financial statements fairly present the company's condition and operations, disclosure controls are effective, and no material weaknesses or fraud involving management were identified. No specific financial metrics, transactions, or operational changes are disclosed in these certification exhibits.
Why this rating
Routine SOX certifications; no substantive business event. Standard periodic filing requirement disclosing no material issues.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.